Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies

doi:10.12114/j.issn.1007-9572.2022.0827

Chinese General Practice ›› 2023, Vol. 26 ›› Issue (17): 2078-2088.DOI: 10.12114/j.issn.1007-9572.2022.0827

Special Issue: 乳腺癌最新文章合辑；肿瘤最新文章合辑

• Original Research • Previous Articles Next Articles

Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies

1. Division of Medical & Surgical Nursing, School of Nursing, Peking University/Evidence-based Nursing Center, Peking University Health Science Center, Beijing 100191, China
2. Department of Nursing, Tianjin Medical University Cancer Institute & Hospital/National Clinical Research Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

Received:2022-08-08 Revised:2022-12-10 Published:2023-06-15 Online:2023-01-18
Contact: LU Qian

基于前瞻性队列研究的Meta分析构建乳腺癌相关淋巴水肿风险预测模型研究

1．100191　北京市，北京大学护理学院内外科教研室　北京大学循证护理研究中心2．300060　天津市，天津医科大学肿瘤医院护理部　国家肿瘤临床医学研究中心　天津市"肿瘤防治"重点实验室　天津市恶性肿瘤临床医学研究中心

通讯作者: 路潜
作者简介:作者贡献：沈傲梅负责研究设计、文献检索、筛选、评价、资料提取分析及原稿写作；符鑫、韦小夏、卞静如、张丽媛负责文献检索、筛选、评价、资料提取及数据分析；路潜、强万敏、庞冬负责研究设计及方法、论文审阅及修订；所有作者确认论文终稿。
基金资助:
国家自然科学基金面上项目（72174011）——健康生态学视角下乳腺癌淋巴水肿风险预测与精准干预策略研究; 天津医科大学肿瘤医院院级课题（H2001）——基于Triangle模型的乳腺癌患者淋巴水肿分层支持管理标准的制定; '未名护理'领军人才科研创新孵化基金项目（LJRC21ZD03）——基于ITHBC的乳腺癌患者淋巴水肿自我管理行为状况及机制研究

1. .png(616KB)

Abstract

Abstract: Background Lymphedema is a common chronic complication bothering breast cancer patients. Early assessment and prediction of the risk for developing breast cancer-related lymphedema (BCRL) is particularly important. However, there is still a lack of an authoritatively recognized and suitably promoted risk prediction model.Objective To construct and validate a risk prediction model for BCRL based on the results of a meta-analysis.Methods Electronic databases including PubMed, Embase, CINAHL, Scopus, Web of Science, Cochrane Library, CNKI, CBM, and Wanfang Data, were searched for prospective cohort studies on risk factors of BCRL from inception to November 2021. Two systematically trained researchers independently screened the literature, extracted data, and assessed the study quality using the Newcastle-Ottawa Scale. Stata 17.0 was used for meta-analysis. The risk factors with significant pooled effect size and their combined risk value were extracted to construct the Logistic risk prediction model. The Logistic and additive risk scoring models were constructed based on regression coefficients and pooled risk values, respectively. The data of 486 breast cancer patients recruited in the breast cancer research center of Peking University People's Hospital, from April 2017 to December 2018, were selected as the validation set. The area under the ROC curve (AUC) and the Hosmer-Lemeshow test were used to evaluate the prediction performance of the risk scoring model. Decision curve analysis was used to evaluate the clinical practicability.Results A total of 49 prospective cohort studies involving 32 543 breast cancer patients were included. Meta-analysis showed that the incidence of BCRL was 20.6%〔95%CI (17.9%, 23.3%) 〕. Among 49 studies, five risk factors with significant pooled effect sizes were reported more than five times, including body mass index (BMI) 〔RR=1.777, 95%CI (1.515, 2.085) 〕, type of breast surgery〔RR=1.320, 95%CI (1.125, 1.549) 〕, type of axillary surgery〔RR=3.058, 95%CI (2.325, 4.020) 〕, radiotherapy〔RR=1.620, 95%CI (1.214, 2.160) 〕, and postoperative complications〔RR=2.373, 95%CI (1.278, 4.405) 〕. The total score for the Logistic risk scoring model ranged from 0 to 34, and that for the additive risk scoring model ranged from 5 to11. The AUCs of Logistic and additive risk scoring models were 0.748〔95%CI (0.701, 0.794) 〕and 0.737〔95%CI (0.691, 0.784) 〕, respectively. The values of Hosmer-Lemeshow test were 0.185 and 0.763, respectively. The optimal cut-off value of the Logistic risk scoring model was 18, with a sensitivity of 81.7%, and a specificity of 43.1%. The optimal cut-off value of the additive risk scoring model was 8.5, the sensitivity was 80.9%, and the specificity was 42.8%. When the probability threshold ranged from 20% to 30%, the model achieved higher net clinical benefit. Conclusion The BCRL risk prediction model based on this meta-analysis has good predictive performance. It can be used as a risk assessment tool for BCRL to guide the hierarchical monitoring and management of BCRL. However, prediction performance and clinical practicability of the model still needs to be validated and optimized in future research.

Key words: Breast cancer lymphedema, Breast neoplasms, Risk factors, Prediction model, Meta-analysis, Prospective cohort studies

摘要： 背景乳腺癌相关淋巴水肿（BCRL）是困扰乳腺癌患者术后常见的慢性并发症，早期评估和预测BCRL风险尤为重要，但目前仍缺乏权威公认、适宜推广的风险预测模型。目的本研究拟基于Meta分析构建并验证乳腺癌患者BCRL风险预测模型。方法计算机检索PubMed、Embase、CINAHL、Scopus、Web of Science、Cochrane Library、中国知网、中国生物医学数据库、万方数据知识服务平台自建库至2021年11月发表的有关BCRL危险因素的前瞻性队列研究。由2名经过系统培训的研究者分别独立筛选文献、提取资料，并采用纽卡斯尔-渥太华量表（NOS）进行质量评价。采用Stata 17.0软件进行Meta分析。根据Meta分析结果提取合并效应量具有显著性的风险因素及合并风险值，构建Logistic回归预测模型。基于回归系数及合并风险值构建Logistic和Additive评分模型。选取2017年4月至2018年12月在北京大学人民医院乳腺中心招募的486例乳腺癌术后患者为模型验证集，采用受试者工作特征（ROC）曲线下面积（AUC）、Hosmer-Lemeshow检验评价评分模型的预测性能，采用决策曲线分析评价预测模型的临床实用性。结果共纳入49项前瞻性队列研究、32 543例乳腺癌患者。Meta分析结果显示，乳腺癌患者BCRL发生率为20.6%〔95%CI（17.9%，23.3%）〕。49项研究中报告次数>5次且Meta分析合并效应量结果具有显著性的危险因素共5个，分别为：体质指数（BMI）〔RR=1.777，95%CI（1.515，2.085）〕、乳腺手术类型〔RR=1.320，95%CI（1.125，1.549）〕、腋窝手术类型〔RR=3.058，95%CI（2.325，4.020）〕、放疗〔RR=1.620，95%CI（1.214，2.160）〕、术后并发症〔RR=2.373，95%CI（1.278，4.405）〕。Logistic及Additive评分模型总分分别为0~34分、5~11分。Logistic及Additive评分模型的AUC分别为0.748〔95%CI（0.701，0.794）〕、0.737〔95%CI（0.691，0.784）〕，Hosmer-Lemeshow检验P值分别为0.185、0.763。Logistic评分模型最佳截断值为18分，灵敏度为81.7%，特异度为43.1%；Additive评分模型最佳截断值为8.5分，灵敏度为80.9%，特异度为42.8%。当阈值概率在20%~30%时，预测模型具有较高的临床净获益。结论基于Meta分析构建的BCRL风险预测模型具有较好的预测性能，可作为BCRL风险评估工具，指导BCRL的分层管理，但其预测性能和临床实用性仍有待进一步验证和优化。

关键词: 乳腺癌淋巴水肿, 乳腺肿瘤, 危险因素, 风险预测模型, Meta分析, 前瞻性队列研究

SHEN Aomei,LU Qian,FU Xin, et al. Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies[J]. Chinese General Practice, 2023, 26(17): 2078-2088. DOI: 10.12114/j.issn.1007-9572.2022.0827.
沈傲梅,路潜,符鑫等. 基于前瞻性队列研究的Meta分析构建乳腺癌相关淋巴水肿风险预测模型研究[J]. 中国全科医学, 2023, 26(17): 2078-2088. DOI: 10.12114/j.issn.1007-9572.2022.0827.

Figures/Tables 8

References 73

[1]	THOMAS M. Breast cancer-related upper limb lymphoedema：an overview[J]. Br J Community Nurs，2021，26(Sup4):S30-35. DOI：10.12968/bjcn.2021.26.Sup4.S30.
[2]	JØRGENSEN M G, TOYSERKANI N M, HANSEN F G，et al. The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment[J]. NPJ Breast Cancer，2021，7(1):70. DOI：10.1038/s41523-021-00276-y.
[3]	张蕊，郑黎强，潘国伟. 疾病发病风险预测模型的应用与建立[J]. 中国卫生统计，2015，32(4):724-726.
[4]	王艺璇，李惠萍，丁晓彤，等. 乳腺癌术后淋巴水肿风险预测模型的研究进展[J]. 中华护理杂志，2018，53(6):740-743. DOI：10.3761/j.issn.0254-1769.2018.06.020.
[5]	WANG L, LI H P, LIU A N，et al. A scoring system to predict arm lymphedema risk for individual Chinese breast cancer patients[J]. Breast Care （Basel），2016，11(1):52-56. DOI：10.1159/000443491.
[6]	LI F L, LU Q, JIN S L，et al. A scoring system for predicting the risk of breast cancer-related lymphedema[J]. Int J Nurs Sci，2020，7(1):21-28. DOI：10.1016/j.ijnss.2019.12.007.
[7]	TSAI C L, CHIH-YANG HSU, CHANG W W，et al. Effects of weight reduction on the breast cancer-related lymphedema：a systematic review and meta-analysis[J]. Breast，2020，52:116-121. DOI：10.1016/j.breast.2020.05.007.
[8]	STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol，2010，25(9):603-605. DOI：10.1007/s10654-010-9491-z.
[9]	OSMAN A, KAMKAR N, SPEECHLEY M，et al. Fall risk-increasing drugs and gait performance in community-dwelling older adults：a systematic review[J]. Ageing Res Rev，2022，77:101599. DOI：10.1016/j.arr.2022.101599.
[10]	REN Q Y, CHEN D, LIU X B，et al. Derivation and validation of a prediction model of end-stage renal disease in patients with type 2 diabetes based on a systematic review and meta-analysis[J]. Front Endocrinol （Lausanne），2022，13:825950. DOI：10.3389/fendo.2022.825950.
[11]	李惠萍，王玲，杨娅娟，等. 乳腺癌患者术后淋巴水肿风险评分系统的构建和评价[J]. 中国全科医学，2014，17(18):2056-2061,2069. DOI：10.3969/j.issn.1007-9572.2014.18.002.
[12]	HIDDING J T, VIEHOFF P B, BEURSKENS C H，et al.Measurement properties of instruments for measuring of lymphedema：systematic review[J]. Phys Ther，2016，96(12):1965-1981. DOI：10.2522/ptj.20150412.
[13]	黄悦勤. 临床流行病学[M]. 4版.北京：人民卫生出版社，2014.
[14]	KUIJER A, DOMINICI L S, ROSENBERG S M，et al. Arm morbidity after local therapy for young breast cancer patients[J]. Ann Surg Oncol，2021，28(11):6071-6082. DOI：10.1245/s10434-021-09947-3.
[15]	KEELEY V. The early detection of breast cancer treatment-related lymphedema of the arm[J]. Lymphat Res Biol，2021，19(1):51-55. DOI：10.1089/lrb.2020.0097.
[16]	KIM H K, JU Y W, LEE J W，et al. Association between number of retrieved sentinel lymph nodes and breast cancer-related lymphedema[J]. J Breast Cancer，2021，24(1):63-74. DOI：10.4048/jbc.2021.24.e9.
[17]	BIDYUT M, ANNESHA S, SHINJINI C，et al. Patient-reported shoulder morbidity and fatigue among the breast cancer survivors：an insight from a tertiary care cancer hospital[J]. Clin Cancer Investig J，2021，10(1):29-35.
[18]	佟洋，史妍萍，翟海昕. 乳腺癌术后乳房再造患者上肢淋巴水肿与体质量指数的相关性分析[J]. 中国医学前沿杂志（电子版），2021，13(10):104-107. DOI：10.12037/YXQY.2021.10-21.
[19]	袁芊芊，侯晋轩，苏科华，等. 基于上肢淋巴引流的乳腺癌术后水肿风险因素分析[J]. 中华普通外科杂志，2021，36(8):579-584. DOI：10.3760/cma.j.cn113855-20210203-00084.
[20]	BRUNELLE C L, ROBERTS S A, HORICK N K，et al. Integrating symptoms into the diagnostic criteria for breast cancer-related lymphedema：applying results from a prospective surveillance program[J]. Phys Ther，2020，100(12):2186-2197. DOI：10.1093/ptj/pzaa162.
[21]	BRUNELLE C L, ROBERTS S A, SHUI A M，et al. Patients who report cording after breast cancer surgery are at higher risk of lymphedema：results from a large prospective screening cohort[J]. J Surg Oncol，2020，122(2):155-163. DOI：10.1002/jso.25944.
[22]	BUNDRED N, FODEN P, TODD C，et al. Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery：a prospective cohort study[J]. Br J Cancer，2020，123(1):17-25. DOI：10.1038/s41416-020-0844-4.
[23]	NAOUM G E, ROBERTS S, BRUNELLE C L，et al. Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control：long-term results from a prospective screening trial[J]. J Clin Oncol，2020，38(29):3430-3438. DOI：10.1200/JCO.20.00459.
[24]	王季，张意辉，张丽娟，等. 体重指数及体重波动对乳腺癌患者上肢淋巴水肿的影响[J]. 中国康复医学杂志，2020，35(2):182-185. DOI：10.3969/j.issn.1001-1242.2020.02.011.
[25]	ARMER J M, BALLMAN K V, MCCALL L，et al. Factors associated with lymphedema in women with node-positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection[J]. JAMA Surg，2019，154(9):800-809. DOI：10.1001/jamasurg.2019.1742.
[26]	GROSS J P, LYNCH C M, FLORES A M，et al. Determining the organ at risk for lymphedema after regional nodal irradiation in breast cancer[J]. Int J Radiat Oncol Biol Phys，2019，105(3):649-658. DOI：10.1016/j.ijrobp.2019.06.2509.
[27]	KHANNA S, GUPTA A K, CHERIAN A J，et al. Post mastectomy lymphedema—a prospective study of incidence and risk factors[J]. Indian J Surg，2019，81(1):16-22. DOI：10.1007/s12262-017-1703-2.
[28]	GROSS J P, SACHDEV S, HELENOWSKI I B，et al. Radiation therapy field design and lymphedema risk after regional nodal irradiation for breast cancer[J]. Int J Radiat Oncol Biol Phys，2018，102(1):71-78. DOI：10.1016/j.ijrobp.2018.03.046.
[29]	RASTOGI K, JAIN S, BHATNAGAR A R，et al. Breast cancer-related lymphedema in postmastectomy patients receiving adjuvant irradiation：a prospective study[J]. Indian J Cancer，2018，55(2):184-189. DOI：10.4103/ijc.IJC_570_17.
[30]	TSAI R J, DENNIS L K, LYNCH C F，et al. Lymphedema following breast cancer：the importance of surgical methods and obesity[J]. Front Womens Health，2018，3(2). DOI：10.15761/FWH.1000144.
[31]	ZOU L, LIU F H, SHEN P P，et al. The incidence and risk factors of related lymphedema for breast cancer survivors post-operation：a 2-year follow-up prospective cohort study[J]. Breast Cancer，2018，25(3):309-314. DOI：10.1007/s12282-018-0830-3.
[32]	张顺康，孙丽云，陈刚. 乳腺癌改良根治术后放疗患者上肢淋巴水肿与腋淋巴结手术结果的相关性分析[J]. 中国癌症杂志，2018，28(1):55-61. DOI：10.19401/j.cnki.1007-3639.2018.01.008.
[33]	RIBEIRO PEREIRA A C P, KOIFMAN R J, BERGMANN A. Incidence and risk factors of lymphedema after breast cancer treatment：10 years of follow-up[J]. Breast，2017，36:67-73. DOI：10.1016/j.breast.2017.09.006.
[34]	ZHANG X P, HE X M, TAND B B，et al. Risk factors of lymphedema on affected side of upper limb after breast cancer surgery-report from a single center of China[J]. Int J Clin Exp Med，2017，10(1):1592-1601.
[35]	ZHU W, LI D, LI X Q，et al. Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema[J]. Anticancer Drugs，2017，28(3):350-355. DOI：10.1097/CAD.0000000000000468.
[36]	KWAN M L, YAO S, LEE V S，et al. Race/ethnicity，genetic ancestry，and breast cancer-related lymphedema in the Pathways Study[J]. Breast Cancer Res Treat，2016，159(1):119-129. DOI：10.1007/s10549-016-3913-x.
[37]	MENEZES M M, BELLO M A, MILLEN E，et al. Breast reconstruction and risk of lymphedema after mastectomy：a prospective cohort study with 10 years of follow-up[J]. J Plast Reconstr Aesthet Surg，2016，69(9):1218-1226. DOI：10.1016/j.bjps.2016.06.001.
[38]	KILBREATH S L, REFSHAUGE K M, BEITH J M，et al. Risk factors for lymphoedema in women with breast cancer：a large prospective cohort[J]. Breast，2016，28:29-36. DOI：10.1016/j.breast.2016.04.011.
[39]	刘风华，胡艳，沈培佩，等. 乳腺癌相关淋巴水肿发病情况及危险因素前瞻性队列研究[J]. 中华放射肿瘤学杂志，2016，25(6):593-597. DOI：10.3760/cma.j.issn.1004-4221.2016.06.011.
[40]	SWAROOP M N, FERGUSON C M, HORICK N K，et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema：results from a large prospective cohort[J]. Breast Cancer Res Treat，2015，151(2):393-403. DOI：10.1007/s10549-015-3408-1.
[41]	BOUGHEY J C, HOSKIN T L, CHEVILLE A L，et al. Risk factors associated with breast lymphedema[J]. Ann Surg Oncol，2014，21(4):1202-1208. DOI：10.1245/s10434-013-3408-5.
[42]	IKEDA K, OGAWA Y, KAJINO C，et al. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients[J]. Eur J Surg Oncol，2014，40(7):818-823. DOI：10.1016/j.ejso.2014.03.023.
[43]	TOGAWA K, MA H Y, SULLIVAN-HALLEY J，et al. Risk factors for self-reported arm lymphedema among female breast cancer survivors：a prospective cohort study[J]. Breast Cancer Res，2014，16(4):414. DOI：10.1186/s13058-014-0414-x.
[44]	JAMMALLO L S, MILLER C L, SINGER M，et al. Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer[J]. Breast Cancer Res Treat，2013，142(1):59-67. DOI：10.1007/s10549-013-2715-7.
[45]	RIDNER S H, DIETRICH M S, STEWART B R，et al. Body mass index and breast cancer treatment-related lymphedema[J]. Support Care Cancer，2011，19(6):853-857. DOI：10.1007/s00520-011-1089-9.
[46]	AVRAHAM T, DALUVOY S V, RIEDEL E R，et al. Tissue expander breast reconstruction is not associated with an increased risk of lymphedema[J]. Ann Surg Oncol，2010，17(11):2926-2932. DOI：10.1245/s10434-010-1112-2.
[47]	CLOUGH-GORR K M, GANZ P A, SILLIMAN R A. Older breast cancer survivors：factors associated with self-reported symptoms of persistent lymphedema over 7 years of follow-up[J]. Breast J，2010，16(2):147-155. DOI：10.1111/j.1524-4741.2009.00878.x.
[48]	GOLDBERG J I, WIECHMANN L I, RIEDEL E R，et al. Morbidity of sentinel node biopsy in breast cancer：the relationship between the number of excised lymph nodes and lymphedema[J]. Ann Surg Oncol，2010，17(12):3278-3286. DOI：10.1245/s10434-010-1155-4.
[49]	HAYES S C, RYE S, BATTISTUTTA D，et al. Prevalence of upper-body symptoms following breast cancer and its relationship with upper-body function and lymphedema[J]. Lymphology，2010，43(4):178-187.
[50]	HELYER L K, VARNIC M, LE L W，et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients[J]. Breast J，2010，16(1):48-54. DOI：10.1111/j.1524-4741.2009.00855.x.
[51]	KWAN M L, DARBINIAN J, SCHMITZ K H，et al. Risk factors for lymphedema in a prospective breast cancer survivorship study：the Pathways Study[J]. Arch Surg，2010，145(11):1055-1063. DOI：10.1001/archsurg.2010.231.
[52]	NORMAN S A, LOCALIO A R, KALLAN M J，et al. Risk factors for lymphedema after breast cancer treatment[J]. Cancer Epidemiol Biomark Prev，2010，19(11):2734-2746. DOI：10.1158/1055-9965.epi-09-1245.
[53]	YANG E J, PARK W B, SEO K S，et al. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors：a prospective cohort study[J]. J Surg Oncol，2010，101(1):84-91. DOI：10.1002/jso.21435.
[54]	MEESKE K A, SULLIVAN-HALLEY J, SMITH A W，et al. Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women[J]. Breast Cancer Res Treat，2009，113(2):383-391. DOI：10.1007/s10549-008-9940-5.
[55]	YEN T W, FAN X L, SPARAPANI R，et al. A contemporary，population-based study of lymphedema risk factors in older women with breast cancer[J]. Ann Surg Oncol，2009，16(4):979-988. DOI：10.1245/s10434-009-0347-2.
[56]	HAYES S, JANDA M, CORNISH B，et al. Lymphedema secondary to breast cancer：how choice of measure influences diagnosis，prevalence，and identifiable risk factors[J]. Lymphology，2008，41(1):18-28.
[57]	PASKETT E D, NAUGHTON M J, MCCOY T P，et al. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors[J]. Cancer Epidemiol Biomarkers Prev，2007，16(4):775-782. DOI：10.1158/1055-9965.EPI-06-0168.
[58]	WILKE L G, MCCALL L M, POSTHER K E，et al. Surgical complications associated with sentinel lymph node biopsy：results from a prospective international cooperative group trial[J]. Ann Surg Oncol，2006，13(4):491-500. DOI：10.1245/ASO.2006.05.013.
[59]	NIWIN'SKA A, TCHÓRZEWSKA H, PROCNER M，et al. The frequency and risk factors of developing lymphedema of the upper extremity after breast conserving therapy[J]. Nowotwory，2005，55(3):213-218.
[60]	OZASLAN C, KURU B. Lymphedema after treatment of breast cancer[J]. Am J Surg，2004，187(1):69-72. DOI：10.1016/j.amjsurg.2002.12.003.
[61]	GELLER B M, VACEK P M, O'BRIEN P，et al. Factors associated with arm swelling after breast cancer surgery[J]. J Womens Health （Larchmt），2003，12(9):921-930. DOI：10.1089/154099903770948159.
[62]	TSAI R J, DENNIS L K, LYNCH C F，et al. The risk of developing arm lymphedema among breast cancer survivors：a meta-analysis of treatment factors[J]. Ann Surg Oncol，2009，16(7):1959-1972. DOI：10.1245/s10434-009-0452-2.
[63]	李娟，苑博，王轶书，等. 乳腺癌患者决策辅助的研究进展[J]. 中南大学学报（医学版），2021，46(2):176-182. DOI：10.11817/j.issn.1672-7347.2021.190584.
[64]	DE VRIEZE T, GEBRUERS N, NEVELSTEEN I，et al. Physical activity level and age contribute to functioning problems in patients with breast cancer-related lymphedema：a multicentre cross-sectional study[J]. Support Care Cancer，2020，28(12):5717-5731. DOI：10.1007/s00520-020-05375-3.
[65]	ZHU Y Q, XIE Y H, LIU F H，et al. Systemic analysis on risk factors for breast cancer related lymphedema[J]. Asian Pac J Cancer Prev，2014，15(16):6535-6541. DOI：10.7314/apjcp.2014.15.16.6535.
[66]	TORGBENU E, LUCKETT T, BUHAGIAR M A，et al. Prevalence and incidence of cancer related lymphedema in low and middle-income countries：a systematic review and meta-analysis[J]. BMC Cancer，2020，20(1):604. DOI：10.1186/s12885-020-07079-7.
[67]	张浩，刘锐芮，朱琳，等. 中国女性乳腺癌相关淋巴水肿危险因素的Meta分析[J]. 中国全科医学，2021，24(26):3349-3358,3376. DOI：10.12114/j.issn.1007-9572.2021.01.206.
[68]	DEMARK-WAHNEFRIED W, CAMPBELL K L, HAYES S C. Weight management and its role in breast cancer rehabilitation[J]. Cancer，2012，118(8 Suppl):2277-2287. DOI：10.1002/cncr.27466.
[69]	LIU Y F, LIU J E, ZHU Y，et al. Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors[J]. Support Care Cancer，2021，29(9):5435-5445. DOI：10.1007/s00520-021-06122-y.
[70]	MARTÍNEZ-JAIMEZ P, ARMORA VERDÚ M, FORERO C G，et al. Breast cancer-related lymphoedema：risk factors and prediction model[J]. J Adv Nurs，2022，78(3):765-775. DOI：10.1111/jan.15005.
[71]	KWAN J Y Y, FAMIYEH P, SU J，et al. Development and validation of a risk model for breast cancer-related lymphedema[J]. JAMA Netw Open，2020，3(11):e2024373. DOI：10.1001/jamanetworkopen.2020.24373.
[72]	RAFN B S, CHRISTENSEN J, LARSEN A，et al. Prospective surveillance for breast cancer-related arm lymphedema：a systematic review and meta-analysis[J]. J Clin Oncol，2022，40(9):1009-1026. DOI：10.1200/JCO.21.01681.
[73]	郑思娣. 基于前瞻性监测模型的乳腺癌患者术后康复研究[D]. 广州：广东药科大学，2019.

步骤	检索式	命中数量（篇）
#1	"Breast Neoplasms" [Mesh]	315 036
#2	"breast cancer" [Title/Abstract] OR "breast neoplasm" [Title/Abstract] OR "breast tumor" [Title/Abstract] OR "breast tumour*" [Title/Abstract] OR "Breast Carcinoma" [Title/Abstract]	328 162
#3	#1 OR #2	409 101
#4	"lymphedema" [MeSH Terms] OR "Breast Cancer Lymphedema" [MeSH Terms]	13 039
#5	"lymphoedema" [Title/Abstract] OR "lymphedema" [Title/Abstract] OR "lymphatic oedema" [Title/Abstract] OR "lymphatic edema" [Title/Abstract] OR "oedema" [Title/Abstract] OR "edema" [Title/Abstract] OR "arm oedema" [Title/Abstract] OR "arm edema" [Title/Abstract] OR "upper extremity oedema" [Title/Abstract] OR "upper limb oedema" [Title/Abstract] OR "upper extremity edema" [Title/Abstract] OR "upper limb edema" [Title/Abstract] OR "breast cancer lymphedema" [Title/Abstract] OR "breast cancer related lymphedema" [Title/Abstract] OR "breast cancer treatment related lymphedema" [Title/Abstract] OR "breast cancer lymphoedema" [Title/Abstract] OR "breast cancer related lymphoedema" [Title/Abstract] OR "breast cancer treatment related lymphoedema" [Title/Abstract] OR "breast cancer related arm lymphedema" [Title/Abstract] OR "lymphedemic" [Title/Abstract] OR "lymphedemic" [Title/Abstract] OR "swelling" [Title/Abstract]	252 930
#6	#4 OR #5	257 765
#7	"Risk Factors" [MeSH Terms] OR "epidemiologic factors" [MeSH Terms]	1 656 289
#8	"risk factor" [Title/Abstract] OR "risk variable" [Title/Abstract] OR "predictor" [Title/Abstract] OR "prediction" [Title/Abstract] OR "predict factor" [Title/Abstract] OR "prognostic factor" [Title/Abstract] OR "prognostic variable" [Title/Abstract] OR "epidemiologic factor" [Title/Abstract] OR "epidemiologic variable" [Title/Abstract] OR "relevant factor" [Title/Abstract] OR "relevant variable" [Title/Abstract] OR "related factor" [Title/Abstract] OR "related variable" [Title/Abstract] OR "contributing factor*" [Title/Abstract]	1 445 977
#9	#7 OR #8	2 646 906
#10	#3 AND #7 AND #11	768
#11	#10 AND （（humans [Filter]） AND （Chinese [Filter] OR English [Filter]））	626

步骤	检索式	命中数量（篇）
#1	"Breast Neoplasms" [Mesh]	315 036
#2	"breast cancer" [Title/Abstract] OR "breast neoplasm" [Title/Abstract] OR "breast tumor" [Title/Abstract] OR "breast tumour*" [Title/Abstract] OR "Breast Carcinoma" [Title/Abstract]	328 162
#3	#1 OR #2	409 101
#4	"lymphedema" [MeSH Terms] OR "Breast Cancer Lymphedema" [MeSH Terms]	13 039
#5	"lymphoedema" [Title/Abstract] OR "lymphedema" [Title/Abstract] OR "lymphatic oedema" [Title/Abstract] OR "lymphatic edema" [Title/Abstract] OR "oedema" [Title/Abstract] OR "edema" [Title/Abstract] OR "arm oedema" [Title/Abstract] OR "arm edema" [Title/Abstract] OR "upper extremity oedema" [Title/Abstract] OR "upper limb oedema" [Title/Abstract] OR "upper extremity edema" [Title/Abstract] OR "upper limb edema" [Title/Abstract] OR "breast cancer lymphedema" [Title/Abstract] OR "breast cancer related lymphedema" [Title/Abstract] OR "breast cancer treatment related lymphedema" [Title/Abstract] OR "breast cancer lymphoedema" [Title/Abstract] OR "breast cancer related lymphoedema" [Title/Abstract] OR "breast cancer treatment related lymphoedema" [Title/Abstract] OR "breast cancer related arm lymphedema" [Title/Abstract] OR "lymphedemic" [Title/Abstract] OR "lymphedemic" [Title/Abstract] OR "swelling" [Title/Abstract]	252 930
#6	#4 OR #5	257 765
#7	"Risk Factors" [MeSH Terms] OR "epidemiologic factors" [MeSH Terms]	1 656 289
#8	"risk factor" [Title/Abstract] OR "risk variable" [Title/Abstract] OR "predictor" [Title/Abstract] OR "prediction" [Title/Abstract] OR "predict factor" [Title/Abstract] OR "prognostic factor" [Title/Abstract] OR "prognostic variable" [Title/Abstract] OR "epidemiologic factor" [Title/Abstract] OR "epidemiologic variable" [Title/Abstract] OR "relevant factor" [Title/Abstract] OR "relevant variable" [Title/Abstract] OR "related factor" [Title/Abstract] OR "related variable" [Title/Abstract] OR "contributing factor*" [Title/Abstract]	1 445 977
#9	#7 OR #8	2 646 906
#10	#3 AND #7 AND #11	768
#11	#10 AND （（humans [Filter]） AND （Chinese [Filter] OR English [Filter]））	626

第一作者	发表时间（年）	国家	样本量（例）	年龄（岁）	水肿例数（例）	发生率（%）	诊断标准	危险因素
KUIJER^[14]	2021	美国	888	37（22~40）	122	13.7	①	ABC
KEELY^[15]	2021	美国	1 100	56±12	251	22.8	②	E
KIM^[16]	2021	韩国	910	腋窝淋巴结清扫（n=595）：52.5±10.4；前哨淋巴结活检（n=315）：51.6±10.5	121	13.3	③	ABCD
BIDYUT^[17]	2021	印度	342	47	144	42.1	①	AB
佟洋^[18]	2021	中国	713	水肿（n=61）：55.17±13.26；非水肿（n=652）：54.81±11.59	61	8.6	③	AD
袁芊芊^[19]	2021	中国	312	48	45	14.4	②	AD
BRUNELLE^[20]	2020	美国	647	56.6（27~83）	64	9.9	②	ABCD
BRUNELLE^[21]	2020	美国	1 181	569例≥55，612例<55	129	10.9	②	ABCDE
BUNDRED^[22]	2020	英国	545	55.7±12.4	122	22.4	②	AE
NAOUM^[23]	2020	美国	1 815	56（24.4，87.9）	171	9.4	②	C
王季^[24]	2020	中国	472	水肿（n=23）：55.57±13.14；非水肿（n=449）：54.83±11.10	23	4.9	①或③	ACD
ARMER^[25]	2019	美国	486	50.1±10.8	284	58.4	②	AD
GROSS^[26]	2019	美国	265	52.6（42.7，62.1）	39	14.7	③	A
KHANNA^[27]	2019	印度	98	76.8%年龄41~60	23	23.5	③	DE
GROSS^[28]	2018	美国	492	50（40~60）	83	16.9	③	AD
RASTOGI^[29]	2018	印度	100	49.5（21~79）	13	13.0	③	AD
TSAI^[30]	2018	美国	522	63	102	19.5	①或③	ABCD
ZOU^[31]	2018	中国	387	50（24，81）	114	29.4	③	ABCD
张顺康^[32]	2018	中国	197	55.94（28~79）	38	19.3	③	C
RIBEIRO PEREIRA^[33]	2017	巴西	964	55.31±12.98	300	31.1	④	ADE
ZHANG^[34]	2017	中国	2 597	49.9±10.1	277	10.7	③	AE
ZHU^[35]	2017	中国	319	18~75	88	27.6	⑤	B
KWAN^[36]	2016	美国	2 953	非水肿60.0±11.9；水肿患者56.0±11.1	342	11.6	①	—
MENEZES^[37]	2016	巴西	622	258例年龄<50，364例年龄≥50	204	32.8	④	B
WANG^[5]	2016	中国	358	>18	114	31.8	③	CDE
KILBREATH^[38]	2016	澳大利亚	450	56.9±11.2	46	10.2	⑥	D
刘风华^[39]	2016	中国	141	51（24，81）	39	27.7	①或③	ABCD
SWAROOP^[40]	2015	美国	1 121	不清楚	59	5.3	⑦	ACD
BOUGHEY^[41]	2014	美国	124	59（36~85）	38	30.7	⑧	AC
IKEDA^[42]	2014	日本	76	非水肿（n=52）：60.8±13.7；水肿患者（n=24）：55.3±9.6	24	31.6	③	CD
TOGAWA^[43]	2014	美国	666	51.5±7.2	190	28.5	①	AB
JAMMOLLO^[44]	2013	美国	787	56（27~89）	39	5.0	②	ACD
RIDENER^[45]	2011	美国	138	58.9±12.3	27	19.6	②或④	A
AVRAHAM^[46]	2010	美国	316	非乳房重建（n=130）：61（30~83）；乳房重建（n=186）：45（27~74）	34	10.8	③	B
CLOUGH-GORR^[47]	2010	美国	400	>65	145	36.3	①	AB
GOLDBERG^[48]	2010	美国	600	56（24~83）	31	5.2	③	ABCDE
HAYES^[49]	2010	澳大利亚	287	54±10	不清楚	NR	⑥	E
HELYER^[50]	2010	加拿大	137	56（36~78）	16	11.7	④	A
KWAN^[51]	2010	美国	997	水肿（n=133）：55.3±11.1；非水肿（n=864）：55.3±11.1	133	13.3	⑧	ABCD
NORMAN^[52]	2010	美国	631	196例<50，435例≥50	238	37.7	①	ABCDE
YANG^[53]	2010	韩国	183	不清楚	22	12.0	⑨	BCD
MEESK^[54]	2009	美国	494	35~64	120	24.2	①	AC
YEN^[55]	2009	美国	1 338	水肿（n=193）：71.9±5.2；非水肿（n=1 145）：72.9±5.6	193	14.4	①	BCD
HAYES^[56]	2008	澳大利亚	287	54±10	41	23.6	①或⑥	AC
PASKETT^[57]	2007	美国	622	38.5±4.9	336	54.0	①	BCD
WILKE^[58]	2006	美国	2 904	56（23~95）	203	7.0	③	A
NIWIN'SKA^[59]	2005	波兰	174	53（28~76）	17	9.8	③	C
OZASLAN^[60]	2004	土耳其	240	50（28~80）	68	28.3	③	AD
GELLER^[61]	2003	美国	145	水肿（n=55）：49.7±8.5；非水肿（n=90）：59.5±12.4	55	37.9	①	BCD

第一作者	发表时间（年）	国家	样本量（例）	年龄（岁）	水肿例数（例）	发生率（%）	诊断标准	危险因素
KUIJER^[14]	2021	美国	888	37（22~40）	122	13.7	①	ABC
KEELY^[15]	2021	美国	1 100	56±12	251	22.8	②	E
KIM^[16]	2021	韩国	910	腋窝淋巴结清扫（n=595）：52.5±10.4；前哨淋巴结活检（n=315）：51.6±10.5	121	13.3	③	ABCD
BIDYUT^[17]	2021	印度	342	47	144	42.1	①	AB
佟洋^[18]	2021	中国	713	水肿（n=61）：55.17±13.26；非水肿（n=652）：54.81±11.59	61	8.6	③	AD
袁芊芊^[19]	2021	中国	312	48	45	14.4	②	AD
BRUNELLE^[20]	2020	美国	647	56.6（27~83）	64	9.9	②	ABCD
BRUNELLE^[21]	2020	美国	1 181	569例≥55，612例<55	129	10.9	②	ABCDE
BUNDRED^[22]	2020	英国	545	55.7±12.4	122	22.4	②	AE
NAOUM^[23]	2020	美国	1 815	56（24.4，87.9）	171	9.4	②	C
王季^[24]	2020	中国	472	水肿（n=23）：55.57±13.14；非水肿（n=449）：54.83±11.10	23	4.9	①或③	ACD
ARMER^[25]	2019	美国	486	50.1±10.8	284	58.4	②	AD
GROSS^[26]	2019	美国	265	52.6（42.7，62.1）	39	14.7	③	A
KHANNA^[27]	2019	印度	98	76.8%年龄41~60	23	23.5	③	DE
GROSS^[28]	2018	美国	492	50（40~60）	83	16.9	③	AD
RASTOGI^[29]	2018	印度	100	49.5（21~79）	13	13.0	③	AD
TSAI^[30]	2018	美国	522	63	102	19.5	①或③	ABCD
ZOU^[31]	2018	中国	387	50（24，81）	114	29.4	③	ABCD
张顺康^[32]	2018	中国	197	55.94（28~79）	38	19.3	③	C
RIBEIRO PEREIRA^[33]	2017	巴西	964	55.31±12.98	300	31.1	④	ADE
ZHANG^[34]	2017	中国	2 597	49.9±10.1	277	10.7	③	AE
ZHU^[35]	2017	中国	319	18~75	88	27.6	⑤	B
KWAN^[36]	2016	美国	2 953	非水肿60.0±11.9；水肿患者56.0±11.1	342	11.6	①	—
MENEZES^[37]	2016	巴西	622	258例年龄<50，364例年龄≥50	204	32.8	④	B
WANG^[5]	2016	中国	358	>18	114	31.8	③	CDE
KILBREATH^[38]	2016	澳大利亚	450	56.9±11.2	46	10.2	⑥	D
刘风华^[39]	2016	中国	141	51（24，81）	39	27.7	①或③	ABCD
SWAROOP^[40]	2015	美国	1 121	不清楚	59	5.3	⑦	ACD
BOUGHEY^[41]	2014	美国	124	59（36~85）	38	30.7	⑧	AC
IKEDA^[42]	2014	日本	76	非水肿（n=52）：60.8±13.7；水肿患者（n=24）：55.3±9.6	24	31.6	③	CD
TOGAWA^[43]	2014	美国	666	51.5±7.2	190	28.5	①	AB
JAMMOLLO^[44]	2013	美国	787	56（27~89）	39	5.0	②	ACD
RIDENER^[45]	2011	美国	138	58.9±12.3	27	19.6	②或④	A
AVRAHAM^[46]	2010	美国	316	非乳房重建（n=130）：61（30~83）；乳房重建（n=186）：45（27~74）	34	10.8	③	B
CLOUGH-GORR^[47]	2010	美国	400	>65	145	36.3	①	AB
GOLDBERG^[48]	2010	美国	600	56（24~83）	31	5.2	③	ABCDE
HAYES^[49]	2010	澳大利亚	287	54±10	不清楚	NR	⑥	E
HELYER^[50]	2010	加拿大	137	56（36~78）	16	11.7	④	A
KWAN^[51]	2010	美国	997	水肿（n=133）：55.3±11.1；非水肿（n=864）：55.3±11.1	133	13.3	⑧	ABCD
NORMAN^[52]	2010	美国	631	196例<50，435例≥50	238	37.7	①	ABCDE
YANG^[53]	2010	韩国	183	不清楚	22	12.0	⑨	BCD
MEESK^[54]	2009	美国	494	35~64	120	24.2	①	AC
YEN^[55]	2009	美国	1 338	水肿（n=193）：71.9±5.2；非水肿（n=1 145）：72.9±5.6	193	14.4	①	BCD
HAYES^[56]	2008	澳大利亚	287	54±10	41	23.6	①或⑥	AC
PASKETT^[57]	2007	美国	622	38.5±4.9	336	54.0	①	BCD
WILKE^[58]	2006	美国	2 904	56（23~95）	203	7.0	③	A
NIWIN'SKA^[59]	2005	波兰	174	53（28~76）	17	9.8	③	C
OZASLAN^[60]	2004	土耳其	240	50（28~80）	68	28.3	③	AD
GELLER^[61]	2003	美国	145	水肿（n=55）：49.7±8.5；非水肿（n=90）：59.5±12.4	55	37.9	①	BCD

第一作者	人群选择				组间可比性	结局测量			总分	第一作者	人群选择				组间可比性	结局测量			总分
第一作者	①	②	③	④	⑤	⑥	⑦	⑧	总分	第一作者	①	②	③	④	⑤	⑥	⑦	⑧	总分
KUIJER^[14]	1	1	1	1	2	0	0	1	7	KILBREATH^[38]	1	1	1	0	2	1	0	1	7
KEELY^[15]	1	1	0	1	2	1	1	0	7	刘风华^[39]	1	1	1	1	2	1	1	0	8
KIM^[16]	1	1	1	1	2	1	1	1	9	SWAROOP^[40]	1	1	1	1	2	1	1	1	9
BIDYUF^[17]	1	1	1	0	2	1	1	0	7	BOUGHEY^[41]	1	0	1	1	2	1	1	1	8
佟洋^[18]	1	1	0	1	2	1	0	1	7	IKEDA^[42]	1	1	0	1	2	1	1	1	8
袁芊芊^[19]	1	1	1	1	2	1	0	0	7	TOGAWA^[43]	1	1	1	0	2	0	1	1	7
BRUNELLE^[20]	1	1	1	1	2	1	1	1	9	JAMMOLLO^[44]	1	1	1	1	2	1	1	1	9
BRUNELLE^[21]	1	1	1	1	2	1	1	1	9	RIDENER^[45]	1	1	1	1	2	1	1	1	9
BUNDRED^[22]	1	1	0	1	2	1	1	1	8	AVRAHAM^[46]	1	1	1	1	2	1	1	1	9
NAOUM^[23]	1	1	1	1	2	1	1	0	8	CLOUGH-GORR^[47]	1	1	1	1	2	0	1	1	8
王季^[24]	1	1	0	1	2	1	1	0	7	GOLDBERG^[48]	1	1	1	0	2	1	1	1	8
ARMER^[25]	1	1	1	1	2	1	1	1	9	HAYES^[49]	1	1	1	1	2	1	1	1	9
GROSS^[26]	1	1	1	1	2	1	1	1	9	HELYER^[50]	1	1	1	1	2	1	1	0	8
KHANNA^[27]	1	1	0	1	2	1	0	1	7	KWAN^[51]	1	1	1	1	2	1	1	0	8
GROSS^[28]	1	1	1	1	2	1	1	1	9	NORMAN^[52]	1	1	1	1	2	0	1	1	8
RASTOGI^[29]	1	1	0	1	2	1	1	1	8	YANG^[53]	1	1	1	0	2	1	0	1	7
TSAI^[30]	1	1	1	1	2	1	1	1	9	MEESK^[54]	1	1	1	1	2	0	1	1	8
ZOU^[31]	1	1	1	1	2	1	1	0	8	YEN^[55]	1	1	1	1	2	0	1	1	8
张顺康^[32]	1	1	1	1	2	1	1	1	9	HAYES^[56]	1	1	1	1	2	1	1	1	9
RIBEIRO PEREIRA^[33]	1	1	1	1	2	1	1	1	9	PASKETT^[57]	1	1	1	0	2	0	1	1	7
ZHANG^[34]	1	1	1	1	2	1	1	1	9	WILKE^[58]	1	1	0	0	2	1	1	1	7
ZHU^[35]	1	1	0	1	2	1	1	0	7	NIWIN'SKA^[59]	1	1	0	1	2	1	1	0	7
KWAN^[36]	1	1	1	1	2	1	1	0	8	OZASLAN^[60]	1	1	1	1	2	1	1	1	9
MENEZES^[37]	1	1	1	1	2	1	1	1	9	GELLER^[61]	1	1	1	1	2	0	1	1	8
WANG^[5]	1	1	1	1	2	1	0	1	8

Constructing a Risk Prediction Model of Breast Cancer-related Lymphedema Based on a Meta-analysis of Prospective Cohort Studies

基于前瞻性队列研究的Meta分析构建乳腺癌相关淋巴水肿风险预测模型研究

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 73

Related Articles 15

Recommended Articles

Metrics

Comments

危险因素	分组	研究数量（篇）	病例数（例）	样本量（例）	模型	I²（%）	P值	RR（95%CI）	Egger's P值	β
BMI	≥30 kg/m²与<30 kg/m²	14^{[15,18,20,22,24,33,43,44,45,47,50,51,52,57]}	1 945	8 819	随机效应模型	30.00	0.144	1.777（1.515，2.085）	0.488	0.575
乳腺手术类型	乳腺切除术与肿物切除术	16^{[14,16,20,21,30,31,35,39,43,47,48,51,52,53,55,61]}	1 786	9 955	随机效应模型	26.50	0.157	1.320（1.125，1.549）	0.809	0.278
腋窝手术类型	ALND与SLNB	10^{[14,16,21,23,24,31,39,41,44,57]}	1 132	7 327	随机效应模型	16.30	0.289	3.058（2.325，4.020）	0.465	1.118
放疗	是与否	12^{[16,25,31,33,39,42,48,51,53,55,57,61]}	1 652	6 849	随机效应模型	61.50	0.003	1.620（1.214，2.160）	0.853	0.482
术后并发症	是与否	6^{[5,21,33,34,48,52]}	1 089	6 331	随机效应模型	74.00	0.002	2.373（1.278，4.405）	—	0.864

风险因素	Logistic评分	Additive评分
BMI（kg/m²）
≥30	6	2
<30	0	1
乳腺手术类型
全乳切除	3	2
肿物切除	0	1
腋窝手术类型
ALND	11	3
SLNB	0	1
放疗
是	5	2
否	0	1
术后并发症
是	9	2
否	0	1

[1]	XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822.
[2]	JIA Gaopeng, CHEN Qiuyu. Construction and Validation of a Risk Prediction Model for Recurrent Angina after Percutaneous Coronary Intervention in Elderly Patients with Acute ST-segment Elevation Myocardial Infarction: Based on CYP2C19-related Genetic Testing [J]. Chinese General Practice, 2025, 28(30): 3779-3786.
[3]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[4]	LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778.
[5]	SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374.
[6]	ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455.
[7]	QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431.
[8]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[9]	JIANG Shihua, ZHU Zheng, REN Yingying, ZHU Yaolei, WANG Yue, GAO Xibin. Meta Analysis of the Prevalence and Risk Factors of Myopia in Chinese Children and Adolescents [J]. Chinese General Practice, 2025, 28(24): 3043-3052.
[10]	LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933.
[11]	WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940.
[12]	ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877.
[13]	ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783.
[14]	MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685.
[15]	HU Wanqin, YU Shenyan, CAO Xuehua, XIANG Feng, JIA Yu. Factors Associated with Precocious Puberty in Chinese Children: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2661-2671.